Search research articles
Contact Us
Filters
Showing results (61-70 of 111) with videos related to
Page
of 12
Sort By:
Nature Communications
|
March 14, 2024
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design
Victoria I Cushing, Adrian F Koh, Junjie Feng, et al.
Breast Cancer Research and Treatment
|
March 13, 2015
Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer
Rezvan Abduljabbar, Ola H Negm, Chun-Fui Lai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 15, 2025
TRIM24 as a therapeutic target in endocrine treatment-resistant breast cancer
Nuno Padrão, Sebastian Gregoricchio, Nils Eickhoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2016
Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts
Jacqueline A Shaw, David S Guttery, Allison Hills, et al.
Elife
|
September 21, 2020
Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments
Hajnalka L Pálinkás, Angéla Békési, Gergely Róna, et al.
Science Signaling
|
June 19, 2014
The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁
Yichen Xu, Hua Zhang, Lei C Lit, et al.
Molecular Cell
|
November 17, 2023
Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition
Gemma A Wilson, Karla Vuina, Georgina Sava, et al.
Oncogene
|
November 24, 2023
Selective inhibition of CDK9 in triple negative breast cancer
Ebtihal H Mustafa, Geraldine Laven-Law, Zoya Kikhtyak, et al.
The Lancet. Oncology
|
June 1, 2005
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
Andreas Polychronis, H Dudley Sinnett, Dimitri Hadjiminas, et al.
Anti-Cancer Drugs
|
December 13, 2024
Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer
Caroline H Rinderle, Christopher V Baker, Courtney B Lagarde, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 111) with videos related to
Sort By:
Page
of 12
Nature Communications
|
March 14, 2024
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design
Victoria I Cushing, Adrian F Koh, Junjie Feng, et al.
Breast Cancer Research and Treatment
|
March 13, 2015
Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer
Rezvan Abduljabbar, Ola H Negm, Chun-Fui Lai, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 15, 2025
TRIM24 as a therapeutic target in endocrine treatment-resistant breast cancer
Nuno Padrão, Sebastian Gregoricchio, Nils Eickhoff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2016
Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts
Jacqueline A Shaw, David S Guttery, Allison Hills, et al.
Elife
|
September 21, 2020
Genome-wide alterations of uracil distribution patterns in human DNA upon chemotherapeutic treatments
Hajnalka L Pálinkás, Angéla Békési, Gergely Róna, et al.
Science Signaling
|
June 19, 2014
The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁
Yichen Xu, Hua Zhang, Lei C Lit, et al.
Molecular Cell
|
November 17, 2023
Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition
Gemma A Wilson, Karla Vuina, Georgina Sava, et al.
Oncogene
|
November 24, 2023
Selective inhibition of CDK9 in triple negative breast cancer
Ebtihal H Mustafa, Geraldine Laven-Law, Zoya Kikhtyak, et al.
The Lancet. Oncology
|
June 1, 2005
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
Andreas Polychronis, H Dudley Sinnett, Dimitri Hadjiminas, et al.
Anti-Cancer Drugs
|
December 13, 2024
Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer
Caroline H Rinderle, Christopher V Baker, Courtney B Lagarde, et al.
Page
of 12